Veterinary Forceps Market Size & Share 2026-2035

Veterinary Forceps Market Size

The global veterinary forceps market was valued at USD 238.2 million in 2025 and is projected to reach USD 444.8 million by 2035, expanding at a 6.6% CAGR. Market value increased from approximately USD 209.5 million in 2022 to USD 227.6 million in 2024 as veterinary providers added surgical capacity and owners authorized a broader range of companion-animal procedures.

Forceps demand follows surgical throughput but is also shaped by the procedure mix: reusable hemostatic and tissue instruments support routine caseloads, whereas orthopedic, ophthalmic, and endoscopic configurations are purchased when practices add specialty capability.

Companion-animal spending provides a durable demand base in mature markets. U.S. pet industry expenditure reached USD 158 billion in 2025, while pet ownership extended to 95 million households, including 71 million dog-owning and 53 million cat-owning households ^{[1]American Pet Products Association, U.S. Pet Industry Reaches $158 Billion in 2025, americanpetproducts.org}. Insurance increasingly converts owner willingness to seek treatment into funded procedures: 6.4 million U.S. pets were insured at year-end 2024, with gross written premiums of USD 4.74 billion ^{[2]North American Pet Health Insurance Association, State of the Industry Report 2025, naphia.org}. These conditions support demand for instruments used in elective, corrective, emergency, dental, and minimally invasive procedures.

Clinical capacity is expanding, although unevenly. The U.S. veterinarian population reached 133,475 in 2025, compared with 124,069 in 2022. Europe adds a similarly substantial companion-animal base, with approximately 299 million pets across 139 million households. At the same time, livestock-health infrastructure in developing economies broadens the addressable market for basic surgical instruments used in field procedures and production-animal care.

North America led the market with USD 94.6 million in 2025, representing 39.7% of global revenue. Europe followed at USD 74.3 million, while Asia Pacific generated USD 53.8 million and is forecast to expand at the fastest regional CAGR of 7.1%. Hemostatic forceps were the largest product category at USD 59.2 million, whereas endoscopic and biopsy forceps are expected to grow fastest at 7.2% CAGR. Companion animals represented USD 150.1 million, or 63.0% of 2025 revenue, and veterinary hospitals accounted for USD 125.2 million, or 52.6%.

Insurance penetration and specialty capacity reinforce this shift. Broader coverage can raise acceptance of complex procedures, which improves the utilization case for endoscopy, orthopedics, and advanced dental services. However, capital requirements and specialist availability prevent this transition from occurring uniformly. Suppliers therefore face a dual market: dependable replacement demand for standard reusable forceps and a faster-growing specialty opportunity concentrated in referral settings.

Key Drivers

Rising Companion Animal Adoption and Rising Animal Healthcare Expenditure

Pet ownership creates the installed base from which veterinary procedure volumes arise, but healthcare expenditure determines the intensity of instrument demand. The U.S. pet industry's USD 158 billion expenditure in 2025 reflects continued spending across veterinary services, diagnostics, medications, and surgical care. As owners increasingly treat companion animals as family members, routine procedures are supplemented by dental, orthopedic, oncologic, and ophthalmic interventions that require broader and more specialized forceps inventories.

Insurance is particularly important because it changes the economics of surgical authorization. U.S. insured-pet numbers increased 12.7% in 2024, while premiums reached USD 4.74 billion. Higher insurance uptake does not automatically produce forceps sales, but it supports provider investment in procedures with greater instrument intensity, especially where emergency treatment or specialty surgery would otherwise be deferred because of out-of-pocket cost.

Europe provides a substantial parallel demand base. The region had approximately 299 million companion animals in 2023, including 108 million cats and 90 million dogs. This population supports recurring requirements for standard surgical sets while giving specialty practices a broad referral pool for procedure-specific instruments.

Growing Number of Veterinary Surgical Procedures

Workforce expansion raises the capacity to convert animal-health demand into performed procedures. The U.S. veterinarian population increased by more than 9,400 practitioners between 2022 and 2025 ^{[3]American Veterinary Medical Association, U.S. Veterinarian Numbers 2025, avma.org}. More clinicians do not create equivalent growth across every forceps category; general-practice capacity supports high-volume soft-tissue and dental demand, while specialty workforce availability has a stronger effect on orthopedic, ophthalmic, and endoscopic instruments.

Minimally invasive veterinary surgery is a notable source of incremental instrument value. Laparoscopic procedures can reduce surgical trauma, postoperative complications, hospitalization time, and recovery time relative to open procedures. The resulting clinical and owner-value proposition encourages referral hospitals and teaching facilities to invest in endoscopic platforms and compatible biopsy, retrieval, and grasping forceps. This mechanism supports the above-market forecast for endoscopic and biopsy forceps even where total surgical volumes grow more gradually.

Expansion of Livestock Healthcare Infrastructure

Livestock healthcare extends the market beyond urban companion-animal clinics. FAO livestock-system resources document the scale and geographic breadth of animal production systems, particularly across Asia and other emerging regions. As production becomes more intensive, animal health management becomes more closely linked to productivity, survival, and reproductive performance, increasing the relevance of professional surgical and wound-management tools.

This demand is weighted toward durable, broadly applicable forceps. Hemostatic, tissue, and dressing instruments are more accessible to field-oriented and mixed-animal practices than capital-intensive endoscopic systems. Consequently, livestock expansion supports market volume and geographic reach, while companion-animal specialty medicine remains the principal driver of premium product mix.

Key Restraints

High Cost of Advanced Veterinary Surgical Instruments

Premium forceps are often purchased as part of a wider procedural investment rather than as isolated tools. Laparoscopic surgery requires equipment, training, and a technically demanding learning curve, which concentrates adoption in referral centers and university hospitals. The forceps opportunity is therefore constrained by a facility's ability to finance an endoscopic platform, maintain sterilization processes, and generate enough case volume to justify specialized inventories.

Reusable instruments also require disciplined reprocessing. Veterinary sterilization practices depend on appropriately selected methods, packaging, monitoring, and maintenance rather than a single universal protocol ^{[4]American Animal Hospital Association, Sterilization Methods in Vet Med: Not One Size Fits All, aaha.org}. For small practices, the combined cost of specialty sets and validated reprocessing capability can delay procurement, favor basic instruments, or extend replacement cycles.

Shortage of Skilled Veterinary Professionals

Aggregate veterinarian growth does not remove specialty and rural-service constraints. The AVMA has reported a shift toward companion-animal practice, while food-animal and mixed-animal practice declined over the preceding decade. This distribution matters because livestock regions may have demand for formal veterinary care but insufficient local capacity to perform a consistent volume of surgical procedures.

Projected graduate supply can improve the overall labor base, yet workforce supply alone does not guarantee geographic distribution or specialty availability. Complex orthopedic, ophthalmic, and neurologic procedures remain concentrated in referral systems, limiting adoption of the most specialized forceps outside larger urban and academic centers. The restraint is operational rather than purely clinical: suppliers may encounter latent demand in under-served regions without a sufficiently dense practitioner base to sustain premium instrument utilization.

A mid-market gap follows from this structure. Basic instruments can meet price-sensitive demand but offer limited differentiation, while complete premium systems remain inaccessible to many advancing clinics. Modular sets, durable reusable instruments, and distribution models that match clinics' staged adoption of surgical capability are likely to be more commercially relevant than a uniform premium portfolio across all regions.

Veterinary Forceps Market Segment Analysis

By Product Type

Hemostatic forceps were the largest product segment, valued at USD 59.2 million in 2025 and projected to reach USD 110.7 million by 2035 at 6.6% CAGR. Their 24.9% market share reflects use across soft-tissue, dental, orthopedic, emergency, and reproductive procedures, where vascular control is essential. Their demand base is broad, which makes the category less dependent on any one specialty pathway.

Tissue forceps generated USD 47.5 million in 2025 and are projected to reach USD 86.0 million by 2035 at 6.3% CAGR. Dressing/sponge forceps accounted for USD 24.4 million and are forecast to reach USD 43.6 million at 6.1% CAGR. Both categories are tied primarily to general surgical volume and reusable-set replacement, resulting in steady but comparatively lower growth than specialty products.

Dental extraction forceps represented USD 29.7 million in 2025 and are forecast to reach USD 54.9 million by 2035 at 6.5% CAGR. Orthopedic forceps accounted for USD 36.9 million and are projected to grow at 6.8% CAGR to USD 70.3 million. The latter category benefits from the higher instrument specificity of bone handling, fracture repair, and joint procedures, where practices procure configured sets rather than isolated standard forceps.

Ophthalmic forceps reached USD 18.3 million in 2025 and are expected to reach USD 35.4 million by 2035 at 7.0% CAGR. Endoscopic and biopsy forceps totaled USD 22.3 million and are projected to reach USD 43.9 million at 7.2% CAGR. These smaller but faster-growing categories reflect a shift toward delicate, specialty, and minimally invasive procedures, where compatibility, tip geometry, and repeat-use performance are commercially important.

By Animal Type

Companion animals represented USD 150.1 million in 2025, or 63.0% of market revenue, and are projected to reach USD 277.5 million by 2035 at 6.5% CAGR. Their dominance is supported by ownership scale, greater owner expenditure, insurance adoption, and the breadth of surgical services available in companion-animal practices.

Livestock animals accounted for USD 69.1 million in 2025 and are forecast to grow at the highest animal-type CAGR, 7.0%, reaching USD 133.6 million by 2035. This growth reflects the formalization of veterinary services in production systems, where forceps support wound management, reproductive work, and surgical interventions. Exotic and zoo animals generated USD 19.0 million in 2025 and are projected to reach USD 33.7 million at 6.1% CAGR; their lower volume is offset by demand for specialized configurations in academic, zoological, and conservation settings.

By Application

Soft tissue surgery was the largest application at USD 66.8 million in 2025, or 28.0% share, and is expected to reach USD 120.7 million by 2035 at 6.2% CAGR. Its scale reflects the breadth of gastrointestinal, urogenital, thoracic, reconstructive, and oncologic procedures that require hemostatic, tissue, and dressing forceps.

Orthopedic surgery generated USD 48.7 million in 2025 and is forecast to reach USD 96.0 million at the fastest application CAGR of 7.2%. Dental surgery accounted for USD 36.8 million and is projected to grow at 7.0% CAGR to USD 71.2 million. Both applications create demand for procedure-specific instrument sets and increasingly support supplier differentiation through configuration breadth and handling precision.

Ophthalmic surgery represented USD 20.0 million in 2025 and is expected to reach USD 36.9 million at 6.5% CAGR. Neurosurgery totaled USD 11.3 million and is forecast to grow to USD 20.1 million at 6.1% CAGR, reflecting its concentration in specialist and academic settings. Endoscopic procedures generated USD 24.4 million and are projected to reach USD 46.6 million at 6.8% CAGR, supported by the clinical advantages associated with minimally invasive treatment ^{[5]Small Animal Advances, Laparoscopy in Veterinary Abdominal Surgery, rovedar.com}. Other surgical procedures accounted for USD 30.2 million and are forecast to reach USD 53.4 million at 6.0% CAGR.

By End Use

Veterinary hospitals led end use with USD 125.2 million in 2025, representing 52.6% of market revenue, and are projected to reach USD 237.7 million by 2035 at 6.8% CAGR. Their lead arises from emergency services, multiple surgical specialties, dedicated operating rooms, and reprocessing infrastructure. These facilities are best positioned to purchase comprehensive inventories spanning standard and specialty forceps.

Veterinary clinics generated USD 91.4 million in 2025 and are expected to reach USD 169.0 million at 6.5% CAGR. Clinics represent the largest channel for routine surgical utilization and a growing channel for mid-tier specialty adoption. Academic and research institutes accounted for USD 21.6 million and are forecast to reach USD 38.1 million at 6.0% CAGR. Their smaller revenue base includes high-specification demand associated with teaching, research, and advanced procedural training.

Hospitals and clinics require different supplier propositions. Hospitals are the principal buyers of broad specialty inventories because they combine advanced caseloads with reprocessing capacity. Clinics drive high-volume use of standard instruments but represent a gradual upgrade opportunity as they internalize procedures previously referred elsewhere. Suppliers able to pair reliable standard lines with modular specialty configurations can address both demand pools without relying solely on premium referral-hospital sales.

Veterinary Forceps Market Regional Analysis

North America

North America was valued at USD 94.6 million in 2025 and is projected to reach USD 170.6 million by 2035 at 6.2% CAGR. The U.S. represented USD 85.7 million, or 90.6% of regional revenue, and is expected to reach USD 151.0 million by 2035. Canada accounted for USD 8.9 million and is forecast to grow faster, at 8.3% CAGR, reaching USD 19.6 million.

The region combines high companion-animal spending, insurance adoption, and clinical specialization. U.S. pet-industry expenditure reached USD 158 billion in 2025, while insured-pet participation continued to expand. FDA guidance states that animal medical devices are not subject to the same premarket approval or 510(k) requirements as human devices, although they remain subject to controls related to adulteration and misbranding. This framework can reduce commercialization friction for veterinary-specific products relative to human-device pathways.

Within North America, hemostatic forceps generated USD 24.2 million in 2025, followed by tissue forceps at USD 18.7 million and orthopedic forceps at USD 14.5 million. Endoscopic and biopsy forceps totaled USD 8.7 million and are forecast to grow at 6.8% CAGR. Companion animals represented USD 59.8 million, or 63.2% of regional revenue. Soft tissue surgery was the largest application at USD 27.2 million, while orthopedic surgery is projected to grow fastest at 6.8% CAGR. Veterinary hospitals accounted for USD 49.9 million, or 52.7% of regional end-use revenue.

Europe

Europe generated USD 74.3 million in 2025 and is projected to reach USD 140.3 million by 2035 at 6.7% CAGR. Its demand base is supported by a large companion-animal population and established veterinary services infrastructure. FEDIAF reported approximately 299 million companion animals in Europe across 41 countries in 2023 ^{[6]FEDIAF, FEDIAF Publishes 2025 Facts and Figures, europeanpetfood.org}, providing sustained demand for both routine and specialty procedures.

Germany, the UK, France, Italy, Spain, and the Netherlands form the core regional coverage. The region's market is shaped by mature clinical networks, specialist referral pathways, and demand for reusable instruments that meet established quality and reprocessing expectations. Where products are marketed for human use as well as veterinary use, EU Medical Device Regulation requirements can add compliance obligations; veterinary-exclusive instruments are governed through applicable national frameworks. This distinction affects supplier portfolio strategy and product-labelling decisions.

Asia Pacific

Asia Pacific was valued at USD 53.8 million in 2025 and is projected to reach USD 105.2 million by 2035 at 7.1% CAGR, the fastest among the regions. China, Japan, India, Australia, and South Korea contribute through different demand mechanisms. Mature companion-animal markets and specialty practices support premium instruments in Japan, Australia, and South Korea, while China and India combine urban pet-care expansion with a large livestock-health opportunity.

FAO resources underline the importance of livestock systems to regional animal-health demand ^{[7]Food and Agriculture Organization of the United Nations, Livestock Systems, fao.org}. The resulting market is not uniform: urban referral centers create demand for endoscopic and orthopedic forceps, whereas expanding production-animal care supports basic hemostatic, tissue, and dressing instruments. This mix gives the region both volume potential and an expanding specialty tier.

Latin America

Latin America generated USD 10.8 million in 2025 and is forecast to reach USD 20.7 million by 2035 at 6.9% CAGR. Brazil, Mexico, and Argentina comprise the covered markets. Companion-animal care in major cities and livestock-related veterinary activity create a mixed demand base, but affordability and currency exposure can favor durable, value-oriented instruments over premium capital-intensive systems.

The regional opportunity is therefore tied to clinic-network development and distributor access as much as to procedure demand. Suppliers that offer reliable standard configurations and serviceable replacement inventories are better aligned with the operating realities of practices that are building surgical capability incrementally.

Middle East & Africa

Middle East & Africa accounted for USD 4.7 million in 2025 and is projected to reach USD 8.0 million by 2035 at 5.7% CAGR. South Africa, Saudi Arabia, and the UAE are the covered markets. Demand is concentrated in urban companion-animal services and in better-developed veterinary facilities, while livestock-health programs provide a longer-term pathway for broader adoption of general surgical instruments.

The region's lower growth rate reflects a smaller installed clinical base and uneven access to specialist services. Demand is likely to remain weighted toward basic reusable forceps until clinical infrastructure, professional capacity, and access to specialized equipment expand more consistently.

Asia Pacific is commercially significant because it combines companion-animal specialization with livestock-health development rather than relying on one demand source. Europe offers a different proposition: a mature companion-animal base with continued specialty-procedure adoption. Latin America presents a selective volume opportunity, but suppliers must match pricing, distribution, and replacement-service models to local purchasing constraints rather than assuming that premium product portfolios will translate directly from North American or European referral markets.

Veterinary Forceps Market Share & Competitive Landscape

The competitive environment spans veterinary specialists, diversified medical-device suppliers, surgical-instrument manufacturers, reprocessing providers, and companies with adjacent animal-health distribution relationships. Product differentiation is concentrated in material durability, precision, locking mechanisms, ergonomic design, sterilization compatibility, procedure-specific configurations, and availability through veterinary distribution channels. The market's fragmentation means that suppliers can compete effectively in selected niches, but specialty growth increasingly rewards portfolios that connect instruments with procedural training, distribution, and post-purchase support.

Integra LifeSciences reported USD 1.06 billion in 2023 revenue for its Codman Specialty Surgical segment, up 3.9% from 2022 ^{[8]Integra LifeSciences, Q4 and Full-Year 2023 Financial Results, integralife.com}. Its scale in precision and specialty surgical instrumentation provides a manufacturing and distribution base relevant to veterinary surgical offerings, including the Miltex line.

Vimian has used acquisitions to broaden its veterinary MedTech reach. In February 2022, its Movora segment acquired Kahu Vet Group, a New Zealand supplier of veterinary surgical products serving more than 700 clinics in Australia and New Zealand ^{[9]Vimian Group, Kahu Vet Group Acquisition, vimian.com}. In April 2022, Movora acquired the Spectrum and Everost product portfolios, adding veterinary surgical instruments and orthopedic implants in North America. The company subsequently announced the acquisition of iM3 Dental, expanding its position in veterinary dental equipment and instruments. This sequence illustrates how portfolio breadth across orthopedics, surgery, and dental care can create cross-selling potential in specialty veterinary channels.

Recent Industry Developments

• February 2022: Vimian Group's Movora segment acquired Kahu Vet Group, a supplier of veterinary surgical products in New Zealand and Australia. Kahu Vet served more than 700 veterinary clinics and reported approximately EUR 8.5 million in 2021 revenue.

• April 2022: Vimian Group's Movora segment acquired the Spectrum and Everost product portfolios, adding veterinary-specific surgical instruments and orthopedic implants. The acquired portfolios had combined annual revenue of approximately USD 6.5 million.

• 2024: Vimian Group announced the acquisition of iM3 Dental, a veterinary dental products and equipment company with approximately EUR 35.9 million in consolidated annual revenue. The transaction expanded Vimian's veterinary dental offering.